GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
Scaling-up pluripotent stem cell (PSC) culture is not simply about “numbering” up. Scale-up is a technique that requires expertise and careful planning. Read the latest CDMO Education Centre post to learn more. https://cdmo.ccrm.ca/blog/scaling-up-production-of-pluripotent-stem-cells-part-1-begin-with-the-end-in-mind-0
“Universal cells: a great solution...to what problem?“ with @enhancerleo, @peretzp, Megan Sykes, @cplanetas, Stephen Sullivan. Sat, 26 Jun at 20:00 on @clubhouse!
Universal cells: a great solution...to what problem? - DESIGNER IMMUNOLOGY
Saturday, June 26 at 12:00pm PDT with Leonardo Ferreira, Peretz Partensky, Megan Sykes, Torsten Meissner, Stephen Sull...
Today's episode is out!
Dr. Stephen Sullivan from the Global Alliance for @iPSCTherapies (GAiT) joins us to discuss the importance of quality in cell therapy products, and how international cooperation can help move therapies from the lab to the clinic.
The CiRA Foundation @CiRA_F_J and
@CCRM_ca will co-chair GAiT's Industry Liaison Committee. This Committee will focus on clarifying the translation roadmap for iPSC therapeutics and how to improve efficiencies.
We pay tribute to the participants of the first iPSC Quality Assessment Round in the Stem Cell Podcast recorded today and look forward to its broadcast on in two weeks time.
The Stem Cell Podcast
Culturing knowledge in stem cell research.
Great interview of Stephen Sullivan, International Liaison Officer at the GAiT @IPSCtherapies a global initiative to support the clinical application of iPSC-based therapies, funded by @nyscf @CGTCatapult @CCRM_ca @Inserm and led by a prestigious scientific advisory board! https://twitter.com/FeyeuxMaxime/status/1397521579366625282
A poll has been sent to Industry Members' emails to schedule the first Industry Liaison Committee Meeting in the coming weeks.
#ISCT2021 Breaking News – ISCT and WHO launch CGT nomenclature standards at ISCT 2021!
Find out more: https://mailchi.mp/isctglobal/te-rmplenary-6252360
We shall be updating Participants of the iPSC Quality Assessment Round on the manuscript shortly. A professional statistician re-analysed the amalgamated dataset to fortify the paper.
GAiT is also planning its first Industry Liaisons committee meeting. Internal discussions with GAiT Director / CCRM President & CEO Michael May, to discuss schedule, materials, and format, will take place this week. GAiT will then reach out to Industry members directly.